RxDoctor Payments Data

Deborah Monahan, NP

Nurse Practitioner · Spokane, WANPI 1215200613

Payments from drug & device makers

$1,112in general payments, 2019–2025

Across 33 payments — averaging $33.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$514
  • Novartis$124
  • Pfizer$102
  • Eisai Inc.$88
  • Bristol Myers Squibb$43
  • Johnson & Johnson$39
  • plus $202 from 7 others

What the payments were for

  • Food & beverage$1,07196%
  • Education$414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,112 in reported general payments places this provider in the 90th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$84,350
Medicare patients
316
Services billed
2,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate14$223,556
EliquisApixaban17$16,145
XareltoRivaroxaban15$8,044
Anastrozole272$4,650
Exemestane12$1,232
Ondansetron OdtOndansetron18$989
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$724
Letrozole40$716
Prochlorperazine Maleate18$349
Oxycodone Hcl15$240
Hydroxyurea20$206
Alendronate Sodium31$204
Gabapentin12$127
Tramadol Hcl13$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$26$223,55614 claims
PfizerEliquis$102$16,14517 claims
Johnson & JohnsonXarelto$39$8,04415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →